Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers
- PMID: 24566712
- DOI: 10.1038/bmt.2014.19
Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers
Abstract
Research on the different mechanisms for crossing HLA barriers has progressed over the past 10 years. General outlines have come into view for a solution to this issue and are often presented as 'haploidentical SCT' immunology. In this review, we discuss several mechanisms that have recently been described in ex vivo and in vivo settings that can either avoid GVHD or promote hematopoietic reconstitution in haploidentical settings. The host and donor T-cell responses to allogeneic HLA molecules are a fundamental obstacle to the successful application of haploidentical transplantation, which results in unacceptably high incidences of GVHD and graft rejection. Thus, the T-cell response is a central factor in the establishment of a novel haploidentical transplant protocol with superior outcomes.
Similar articles
-
Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.Semin Oncol. 2012 Dec;39(6):683-93. doi: 10.1053/j.seminoncol.2012.09.005. Semin Oncol. 2012. PMID: 23206845 Free PMC article. Review.
-
Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.Ann Hematol. 2019 Mar;98(3):753-762. doi: 10.1007/s00277-019-03593-2. Epub 2019 Jan 8. Ann Hematol. 2019. PMID: 30617644
-
Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.Ann Hematol. 2017 Aug;96(8):1373-1377. doi: 10.1007/s00277-017-3030-x. Epub 2017 Jun 1. Ann Hematol. 2017. PMID: 28573314
-
Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.J Clin Oncol. 2016 Sep 10;34(26):3141-9. doi: 10.1200/JCO.2015.66.3476. Epub 2016 Jun 6. J Clin Oncol. 2016. PMID: 27269951 Free PMC article.
-
Who is the best donor for haploidentical stem cell transplantation?Semin Hematol. 2019 Jul;56(3):194-200. doi: 10.1053/j.seminhematol.2018.08.003. Epub 2018 Aug 24. Semin Hematol. 2019. PMID: 31202430 Review.
Cited by
-
Improving the clinical outcome of unmanipulated haploidentical blood and marrow transplantation.Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S21-3. doi: 10.1038/bmt.2015.90. Bone Marrow Transplant. 2015. PMID: 26039202 Review.
-
Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation.Front Med. 2019 Feb;13(1):45-56. doi: 10.1007/s11684-017-0595-7. Epub 2018 Apr 19. Front Med. 2019. PMID: 29675688 Review.
-
Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study.BMC Med. 2019 Aug 12;17(1):156. doi: 10.1186/s12916-019-1393-7. BMC Med. 2019. PMID: 31401973 Free PMC article. Clinical Trial.
-
Update of the "Beijing Protocol" haplo-identical hematopoietic stem cell transplantation.Bone Marrow Transplant. 2019 Aug;54(Suppl 2):703-707. doi: 10.1038/s41409-019-0605-2. Bone Marrow Transplant. 2019. PMID: 31431695 Review.
-
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?J Hematol Oncol. 2016 Apr 12;9:35. doi: 10.1186/s13045-016-0265-2. J Hematol Oncol. 2016. PMID: 27071449 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous